They copy the action of the natural hormone glucagon-like-peptide-1 and regulate hunger and digestion
In recent years, a class of medications known as GLP-1 receptor agonists (GLP-1s) has gained tremendous attention
Association learning is impaired in insulin resistance and restored by liraglutide
In addition to Semaglutide, Other variants like Mounjaro (GLP-1/GIP agonist), Carinlintide (amylin mimetic), and Retatrutide (GLP-1/GIP/glucagon agonist) also support weight loss by enhancing natural GLP-1 signalling
however, since then, four states (California, New Hampshire, Pennsylvania, and South Carolina) have eliminated coverage of GLP-1s for obesity treatment, likely reflecting recent state budget challenges and the significant costs associated with coverage
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes